Key result
Emerging norovirus antiviral strategies include classical viral protein inhibitors, host factor targets, and lethal mutagenesis.
This review highlights progress in developing norovirus antivirals, including classical inhibitors and novel lethal mutagenesis strategies.
May inform antiviral development for chronic norovirus in immunocompromised patients; leaves open human efficacy and safety trials.
Human noroviruses are a leading cause of gastroenteritis worldwide, yet there are no licensed antivirals. There is an urgent need for norovirus therapeutics, particularly for chronic infections in immunocompromised individuals, but also a potential need for prophylactic use in epidemics. Continued research has led to the identification of compounds that inhibit norovirus replication in vitro and, at least in some cases, are also effective in vivo against murine norovirus. Progress has included classical approaches targeting viral proteins and harnessing the antiviral action of interferon, strategies targeting essential host cell factors, and novel strategies exploiting the high mutation rate of noroviruses.
No takes yet. Share an insight, caveat, or question.
Thorne et al. (2016) conducted a review in Norovirus infection. Norovirus antivirals was evaluated. Continued research has identified various strategies for norovirus antivirals, including classical viral protein inhibitors, host factor targets, and lethal mutagenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: